<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151461</url>
  </required_header>
  <id_info>
    <org_study_id>NS-0100-01</org_study_id>
    <nct_id>NCT02151461</nct_id>
  </id_info>
  <brief_title>Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients</brief_title>
  <official_title>A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuSirt Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NuSirt Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to demonstrate that leucine in combination with a low does of
      metformin can serve as an adjunct to diet and exercise to improve blood glucose levels in
      type 2 diabetic subjects. This study will compare three doses of a leucine-metformin
      combination to the standard metformin dose in controlling blood glucose levels in type 2
      diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, 4-week, active-controlled, double-blind study to evaluate the effect of
      various fixed-dose combinations of leucine and metformin compared to standard metformin
      monotherapy on glycemic control. In this study, standard metformin therapy will be defined as
      1000 g/day for Day 1 to Day 14 and then escalated to 1700 g/day for Day 15 to Day 28.
      Subjects meeting all inclusion criteria and no exclusion criteria will be randomized to one
      of four treatment arms.

      The primary objective of the study is to evaluate the change in fasting plasma glucose from
      Baseline (Day 1) to Week 4 (Day 28) in subjects receiving various fixed-dose combinations of
      leucine and metformin compared to standard metformin monotherapy. Secondary objectives will
      also assess changes in baseline-corrected plasma glucose and insulin area under the
      concentration curves from baseline to day 28 and changes in insulin secretory rates as
      assessed during a 3-hour meal tolerance test. Finally the effects of gastrointestinal
      symptoms will be assessed by subject questionnaires.

      The study will include a total of 3 periods: screening or washout of current diabetic
      monotherapy, a pre-treatment period to ensure subjects will be compliant, and a treatment
      period of 4 weeks, with the first dosing of medication on day 1 of the study. Each day blood
      glucose readings will be measured and recorded by patients. Three-hour standardized meal
      tests will be performed at Baseline (Day 1) and at Study Termination (Day 28). In addition,
      two, 7-day continuous glucose assessments will be conducted, as well as two seven point
      glucose profiles. Patients will also be asked about any gastrointestinal side effects they
      experience.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr</measure>
    <time_frame>0, 15min, 30min, 45min, 1hr, 1.5hrs, 2hrs, 2.5hrs and 3 hrs</time_frame>
    <description>The primary endpoint for NS 0100 01 was the absolute plasma glucose AUC (0-3 hr) change from Day 1 to Day 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in Incremental Plasma Glucose Area Under the Curve (AUC)</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>The baseline incremental (baseline-subtracted) glucose AUC0-3h was evaluated for treatment differences at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>Change in fasting plasma glucose for the fixed dose leucine and metformin combination treatments A, B and C was evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>Changes in HbA1c which is a marker of long-term glucose control was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis Model Assessment-estimated Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>Effect on insulin sensitivity across fixed-dose leucine and metformin combination treatments or the standard metformin reference treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change In 7-Point Glucose Profiles</measure>
    <time_frame>Baseline, Day 7, Day 21, Day 28</time_frame>
    <description>The meal induced glucose change in pre-meal and post-meal glucose were measured 7 times during the day. Subjects self-monitored blood glucose (preprandial and postprandial) concentrations at least 7 times, including before and 1 to 2 hours after breakfast, lunch, dinner, and snacks). For each study day, the pre-meal values from the 7 point test for each subject were averaged to generate a single pre-meal glucose value. Similarly, for each study day the post-meal values from the 7-point test for each subject were averaged to generate a single post-meal glucose value. The average change from baseline (i.e., [(Mean Pre/Post-meal value at Day 28 - Mean Pre/Post-meal value at Baseline) + (Mean Pre/Post-meal value at Day 21- Mean Pre/Post-meal value at Baseline) + (Mean Pre/Post-meal value at Day 7- Mean Pre/Post-meal value at Baseline)]/ 3) over multiple time points listed in Time Frame. The mean pre-meal and post-meal values for baseline, day7, day 21 and day28 were used for comparison.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Insulin Absolute and Incremental Meal Tolerance Test Area Under the Curve (AUC) 0-2hr</measure>
    <time_frame>Baseline,Day 28</time_frame>
    <description>Change in meal tolerance test insulin area under the curve (0-2 hr) from Day 1 to Day 28 for fixed-dose leucine and metformin combination treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in Fasting Plasma Insulin Concentration</measure>
    <time_frame>Baseline, Day 28</time_frame>
    <description>Effect on fasting plasma insulin concentrations across fixed-dose leucine and metformin combination treatments or the standard metformin reference treatment was evaluated.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Low Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 Capsules BID each containing 166.7 mg of metformin with dose escalation to 283.3 mg capsules BID (1,700 mg/Day) at Day 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Metformin</intervention_name>
    <description>1100 mg L Leucine in combination with 125 mg of Metformin BID</description>
    <arm_group_label>Low Metformin</arm_group_label>
    <other_name>Metformin</other_name>
    <other_name>Leucine</other_name>
    <other_name>L-Leucine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID</description>
    <arm_group_label>Metformin Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mid Metformin</intervention_name>
    <description>1100 mg of Leucine in combination with 250 mg Metformin BID</description>
    <arm_group_label>Mid Metformin</arm_group_label>
    <other_name>Metformin</other_name>
    <other_name>Leucine</other_name>
    <other_name>L-Leucine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Metformin</intervention_name>
    <description>1100 mg of Leucine in combination with 500 mg Metformin BID</description>
    <arm_group_label>High Metformin</arm_group_label>
    <other_name>Metformin</other_name>
    <other_name>Leucine</other_name>
    <other_name>L-Leucine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over age 18 at study entry.

          -  Male, or female, if female, meets all of the following criteria:

          -  Not breastfeeding

          -  Post-menopausal or negative pregnancy test result (human chorionic gonadotropin, beta
             subunit [β- hCG]) at Screening (Visit 1) (not required for hysterectomized females)

          -  If of childbearing potential and sexually active, must practice and be willing to
             continue to practice appropriate birth control

          -  Is diagnosed with type 2 diabetes mellitus and either not adequately controlled by:
             diet and exercise alone or diet and exercise plus a single, first line treatment for
             type 2 diabetes.

          -  If treated with an oral anti-diabetes agent, be willing and able to withdraw from
             therapy for 4 weeks after the screening visit and prior to initiating study mediation
             at Baseline (Day 1/Visit 4).

          -  Be willing to avoid acetaminophen use for intervals up to 10 days as required for
             study procedures (see Section 4.6)

          -  Has a fasting plasma glucose ≥126 mg/dL to ≤220 mg/dL at Screening

          -  Has an HbA1c ≥7% to ≤8.5% at Screening

          -  Has a BMI ≤40 kg/m2

          -  Clinical laboratory tests (hematology, clinical chemistry, and urinalysis) either
             normal or abnormal but consistent with type 2 diabetes mellitus.

          -  Is able to read, understand, and sign the informed consent forms (ICF) and if
             applicable, an authorization to use and disclose protected health information form
             (consistent with health insurance portability and accountability act of 1996 [HIPAA]
             legislation), communicate with the investigator, and understand and comply with
             protocol requirements.

        Exclusion Criteria:

          -  Clinically significant renal dysfunction

          -  If using any of the following medications, has not been on a stable treatment regimen
             for a minimum of 4 weeks prior to screening:

        Lipid-lowering agents Anti-hypertensive medications Thyroid replacement therapy
        Non-steroidal anti-inflammatory agents

          -  Unable to perform self-blood glucose monitoring employing a glucose meter.

          -  History of active cardio- or cerebro-vascular disease with an event within the
             previous 6 months

          -  Gastrointestinal disorders

          -  Endocrine disorders other than type 2 diabetes

          -  Chronic infection

          -  Hepatic disease

          -  Neurological or psychiatric diseases

          -  History of other psychiatric disorders

          -  Has been treated (within the last month), is currently treated, or is expected to
             require or undergo treatment with; any anti-diabetes medications (other than as
             allowed by the inclusion criteria), oral or parenteral steroids.

          -  Participation in a weight loss program within the past 3 months.

          -  Weight change by more than 10 pounds during the past month.

          -  History of alcohol or substance abuse in the past 3 months or a positive screen for
             alcohol or drugs of abuse at screening.

          -  Has received any investigational drug within 3 months of Screening.

          -  Has donated blood within 3 months before Screening or is planning to donate blood
             during the study.

          -  Has known allergies or hypersensitivity to metformin or leucine

          -  Is employed, contracted or has an immediate family member directly affiliated with
             NuSirt Biopharma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orville G Kolterman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NuSirt Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catalina Research Institute</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <zip>91710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research</name>
      <address>
        <city>Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>River Birch Research Alliance</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <zip>30513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Research</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Streling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research South</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meharry Medical College</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center, Diabetes, Endocrinology, and Metabolism</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <results_first_submitted>September 21, 2017</results_first_submitted>
  <results_first_submitted_qc>January 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 2, 2018</results_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects meeting all inclusion criteria and no exclusion criteria were randomized to one of four treatment arms in the ratio of 1:1:1:1 (A:B:C:D). The randomization was stratified by fasting plasma glucose (≥126 mg/dL to &lt;200 mg/dL, and ≥200 mg/dL to ≤220 mg/dL), as well as metformin experience. Yes/No history of abdominal side effects.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>FDC125</title>
          <description>Leucine 1100mg +Metformin 125mg</description>
        </group>
        <group group_id="P2">
          <title>FDC250</title>
          <description>Leucine 1100mg +Metformin 250mg</description>
        </group>
        <group group_id="P3">
          <title>FDC500</title>
          <description>Leucine 1100mg +Metformin 500mg</description>
        </group>
        <group group_id="P4">
          <title>Control</title>
          <description>Day 1-14: 500mg, Day 15-28: 850mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who had adequate exposure to the randomized study medication during the 4-week treatment period (Day 1/Visit 4 to Day 28/Visit 7) and had adequately complied with the protocol as assessed by the sponsor prior to database lock.The groups in Metformin experience are mutually exclusive.</population>
      <group_list>
        <group group_id="B1">
          <title>FDC125</title>
          <description>Leucine 1100mg +Metformin 125mg</description>
        </group>
        <group group_id="B2">
          <title>FDC250</title>
          <description>Leucine 1100mg +Metformin 250mg</description>
        </group>
        <group group_id="B3">
          <title>FDC500</title>
          <description>Leucine 1100mg +Metformin 500mg</description>
        </group>
        <group group_id="B4">
          <title>Control</title>
          <description>Day 1-14: 500mg, Day 15-28: 850mg</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="23"/>
            <count group_id="B5" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Subjects who met the inclusion criteria, with FPG&gt;126 to &lt;220 mg/dL, HbA1c&gt;7 to&lt;8.5% and BMI&lt;40kgm2</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.6" spread="9.87"/>
                    <measurement group_id="B2" value="55.1" spread="8.3"/>
                    <measurement group_id="B3" value="56.1" spread="10.08"/>
                    <measurement group_id="B4" value="59.3" spread="9.64"/>
                    <measurement group_id="B5" value="56.0" spread="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.049" spread="17.3747"/>
                    <measurement group_id="B2" value="88.584" spread="19.4687"/>
                    <measurement group_id="B3" value="84.493" spread="19.8622"/>
                    <measurement group_id="B4" value="86.777" spread="16.5700"/>
                    <measurement group_id="B5" value="86.745" spread="18.1696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.142" spread="4.7113"/>
                    <measurement group_id="B2" value="30.985" spread="5.5766"/>
                    <measurement group_id="B3" value="29.927" spread="5.1504"/>
                    <measurement group_id="B4" value="31.146" spread="4.5838"/>
                    <measurement group_id="B5" value="30.798" spread="4.9778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194.3" spread="50.86"/>
                    <measurement group_id="B2" value="170.3" spread="44.28"/>
                    <measurement group_id="B3" value="182.8" spread="40.97"/>
                    <measurement group_id="B4" value="184.7" spread="50.87"/>
                    <measurement group_id="B5" value="182.9" spread="46.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Haemoglobin A1c (HbA1c)</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.95" spread="0.837"/>
                    <measurement group_id="B2" value="8.01" spread="0.713"/>
                    <measurement group_id="B3" value="7.82" spread="0.563"/>
                    <measurement group_id="B4" value="8.24" spread="0.831"/>
                    <measurement group_id="B5" value="8.00" spread="0.747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Metformin experience</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>No Previous Experience</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Abdominal side effects from prior Metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had Abdominal side effects from prior Metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr</title>
        <description>The primary endpoint for NS 0100 01 was the absolute plasma glucose AUC (0-3 hr) change from Day 1 to Day 28.</description>
        <time_frame>0, 15min, 30min, 45min, 1hr, 1.5hrs, 2hrs, 2.5hrs and 3 hrs</time_frame>
        <population>Mixed Model Inferential Statistical Analysis of Plasma Glucose AUC change from day 1-day 28 Evaluable Population (n=73)</population>
        <group_list>
          <group group_id="O1">
            <title>FDC125</title>
            <description>Leucine 1100mg +Metformin 125mg</description>
          </group>
          <group group_id="O2">
            <title>FDC250</title>
            <description>Leucine 1100mg +Metformin 250mg</description>
          </group>
          <group group_id="O3">
            <title>FDC500</title>
            <description>Leucine 1100mg +Metformin 500mg</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Day 1-14: 500mg, Day 15-28: 850mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr</title>
          <description>The primary endpoint for NS 0100 01 was the absolute plasma glucose AUC (0-3 hr) change from Day 1 to Day 28.</description>
          <population>Mixed Model Inferential Statistical Analysis of Plasma Glucose AUC change from day 1-day 28 Evaluable Population (n=73)</population>
          <units>mg*hrs/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.005" spread="142.8374"/>
                    <measurement group_id="O2" value="-45.029" spread="114.6701"/>
                    <measurement group_id="O3" value="-64.010" spread="146.0917"/>
                    <measurement group_id="O4" value="-141.848" spread="194.9300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A mixed-effects model for analysis of covariance (ANCOVA) was used to analyze changes from Baseline in plasma glucose AUC(0-3hr) at Week 4 in the Day 28 Evaluable population. The model includes factors for treatment group and fasting plasma glucose stratum.</non_inferiority_desc>
            <p_value>0.0435</p_value>
            <p_value_desc>Baseline plasma glucose AUC(0-3hr) is adjusted as a covariate.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.065</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1216</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in Incremental Plasma Glucose Area Under the Curve (AUC)</title>
        <description>The baseline incremental (baseline-subtracted) glucose AUC0-3h was evaluated for treatment differences at baseline.</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>Mixed Model Inferential Statistical Analysis of Incremental Plasma Glucose AUC change from day 1-day 28 Evaluable Population (n=73)</population>
        <group_list>
          <group group_id="O1">
            <title>FDC125</title>
            <description>Leucine 1100mg +Metformin 125mg</description>
          </group>
          <group group_id="O2">
            <title>FDC250</title>
            <description>Leucine 1100mg +Metformin 250mg</description>
          </group>
          <group group_id="O3">
            <title>FDC500</title>
            <description>Leucine 1100mg +Metformin 500mg</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Day 1-14: 500mg, Day 15-28: 850mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in Incremental Plasma Glucose Area Under the Curve (AUC)</title>
          <description>The baseline incremental (baseline-subtracted) glucose AUC0-3h was evaluated for treatment differences at baseline.</description>
          <population>Mixed Model Inferential Statistical Analysis of Incremental Plasma Glucose AUC change from day 1-day 28 Evaluable Population (n=73)</population>
          <units>mg*hrs/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.338" spread="60.2834"/>
                    <measurement group_id="O2" value="-17.614" spread="93.1243"/>
                    <measurement group_id="O3" value="-23.061" spread="64.6290"/>
                    <measurement group_id="O4" value="-29.604" spread="86.1126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A mixed-effects model for analysis of covariance (ANCOVA) was used to analyze changes from Baseline in incremental plasma glucose AUC at Week 4 in the Day 28 Evaluable population. The model will include factors for treatment group and fasting plasma glucose stratum.</non_inferiority_desc>
            <p_value>0.8867</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes factors for treatment group and fasting plasma glucose stratum.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7641</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2518</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose</title>
        <description>Change in fasting plasma glucose for the fixed dose leucine and metformin combination treatments A, B and C was evaluated.</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>Mixed Model Inferential Statistical Analysis of Fasting Plasma Glucose change from day 1-day 28 Evaluable Population (n=73)</population>
        <group_list>
          <group group_id="O1">
            <title>FDC125</title>
            <description>Leucine 1100mg +Metformin 125mg</description>
          </group>
          <group group_id="O2">
            <title>FDC250</title>
            <description>Leucine 1100mg +Metformin 250mg</description>
          </group>
          <group group_id="O3">
            <title>FDC500</title>
            <description>Leucine 1100mg +Metformin 500mg</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Day 1-14: 500mg, Day 15-28: 850mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose</title>
          <description>Change in fasting plasma glucose for the fixed dose leucine and metformin combination treatments A, B and C was evaluated.</description>
          <population>Mixed Model Inferential Statistical Analysis of Fasting Plasma Glucose change from day 1-day 28 Evaluable Population (n=73)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="36.91"/>
                    <measurement group_id="O2" value="-9.7" spread="26.50"/>
                    <measurement group_id="O3" value="-13.4" spread="38.55"/>
                    <measurement group_id="O4" value="-36.0" spread="47.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0179</p_value>
            <method>ANCOVA</method>
            <method_desc>Total daily dose is twice the respective dose, Pairwise comparison using Treatment D as the reference group</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0736</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0475</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin A1c (HbA1c)</title>
        <description>Changes in HbA1c which is a marker of long-term glucose control was assessed.</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>Mixed Model Inferential Statistical Analysis of HbA1c change from day 1-day 28 Evaluable Population (n=73)</population>
        <group_list>
          <group group_id="O1">
            <title>FDC125</title>
            <description>Leucine 1100mg +Metformin 125mg</description>
          </group>
          <group group_id="O2">
            <title>FDC250</title>
            <description>Leucine 1100mg +Metformin 250mg</description>
          </group>
          <group group_id="O3">
            <title>FDC500</title>
            <description>Leucine 1100mg +Metformin 500mg</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Day 1-14: 500mg, Day 15-28: 850mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin A1c (HbA1c)</title>
          <description>Changes in HbA1c which is a marker of long-term glucose control was assessed.</description>
          <population>Mixed Model Inferential Statistical Analysis of HbA1c change from day 1-day 28 Evaluable Population (n=73)</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.448"/>
                    <measurement group_id="O2" value="-0.16" spread="0.485"/>
                    <measurement group_id="O3" value="-0.01" spread="0.442"/>
                    <measurement group_id="O4" value="-0.23" spread="0.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0089</p_value>
            <method>ANCOVA</method>
            <method_desc>Total daily dose is twice the respective dose. Pairwise Comparison using Treatment D as the Reference Group</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.376</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0578</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Homeostasis Model Assessment-estimated Insulin Resistance (HOMA-IR)</title>
        <description>Effect on insulin sensitivity across fixed-dose leucine and metformin combination treatments or the standard metformin reference treatment.</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>Mixed Model Inferential Statistical Analysis of HOMA-IR. Some of the samples collected were not viable and could not be included in the analysis. So, the total samples collected were still the same but since they could not be included in the analysis the exact number analyzed is referenced.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC125</title>
            <description>Leucine 1100mg +Metformin 125mg</description>
          </group>
          <group group_id="O2">
            <title>FDC250</title>
            <description>Leucine 1100mg +Metformin 250mg</description>
          </group>
          <group group_id="O3">
            <title>FDC500</title>
            <description>Leucine 1100mg +Metformin 500mg</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Day 1-14: 500mg, Day 15-28: 850mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Homeostasis Model Assessment-estimated Insulin Resistance (HOMA-IR)</title>
          <description>Effect on insulin sensitivity across fixed-dose leucine and metformin combination treatments or the standard metformin reference treatment.</description>
          <population>Mixed Model Inferential Statistical Analysis of HOMA-IR. Some of the samples collected were not viable and could not be included in the analysis. So, the total samples collected were still the same but since they could not be included in the analysis the exact number analyzed is referenced.</population>
          <units>HOMA units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="1.010"/>
                    <measurement group_id="O2" value="-0.14" spread="0.548"/>
                    <measurement group_id="O3" value="0.11" spread="0.958"/>
                    <measurement group_id="O4" value="-0.18" spread="1.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The HOMA Calculator,is an algorithm that takes account of variations in hepatic and peripheral glucose resistance, increases in insulin secretion curve for plasma glucose concentrations above 10 mmol/L (180 mg/dL), and contribution of circulating proinsulin (eg, C-peptide) to estimate steady state beta cell function (%HOMA-B) and insulin sensitivity (%HOMA-S), as percentages of a normal reference population. %HOMA-IR was analyzed on a logarithmic scale (natural logarithmic transformation).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2177</p_value>
            <method>ANCOVA</method>
            <method_desc>Total daily dose is twice the respective dose. Pairwise Comparison using Treatment D as the Reference Group</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4144</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3117</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change In 7-Point Glucose Profiles</title>
        <description>The meal induced glucose change in pre-meal and post-meal glucose were measured 7 times during the day. Subjects self-monitored blood glucose (preprandial and postprandial) concentrations at least 7 times, including before and 1 to 2 hours after breakfast, lunch, dinner, and snacks). For each study day, the pre-meal values from the 7 point test for each subject were averaged to generate a single pre-meal glucose value. Similarly, for each study day the post-meal values from the 7-point test for each subject were averaged to generate a single post-meal glucose value. The average change from baseline (i.e., [(Mean Pre/Post-meal value at Day 28 - Mean Pre/Post-meal value at Baseline) + (Mean Pre/Post-meal value at Day 21- Mean Pre/Post-meal value at Baseline) + (Mean Pre/Post-meal value at Day 7- Mean Pre/Post-meal value at Baseline)]/ 3) over multiple time points listed in Time Frame. The mean pre-meal and post-meal values for baseline, day7, day 21 and day28 were used for comparison.</description>
        <time_frame>Baseline, Day 7, Day 21, Day 28</time_frame>
        <population>Mixed Model Inferential Statistical Analysis of 7 point glucose change from day 1-day 28 Evaluable Population (n=73). Some of the samples collected were not viable and could not be included in the analysis. The total samples collected were still the same but since they could not be included in the analysis the exact number analyzed is referenced.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC125</title>
            <description>Leucine 1100mg +Metformin 125mg</description>
          </group>
          <group group_id="O2">
            <title>FDC250</title>
            <description>Leucine 1100mg +Metformin 250mg</description>
          </group>
          <group group_id="O3">
            <title>FDC500</title>
            <description>Leucine 1100mg +Metformin 500mg</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Day 1-14: 500mg, Day 15-28: 850mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change In 7-Point Glucose Profiles</title>
          <description>The meal induced glucose change in pre-meal and post-meal glucose were measured 7 times during the day. Subjects self-monitored blood glucose (preprandial and postprandial) concentrations at least 7 times, including before and 1 to 2 hours after breakfast, lunch, dinner, and snacks). For each study day, the pre-meal values from the 7 point test for each subject were averaged to generate a single pre-meal glucose value. Similarly, for each study day the post-meal values from the 7-point test for each subject were averaged to generate a single post-meal glucose value. The average change from baseline (i.e., [(Mean Pre/Post-meal value at Day 28 - Mean Pre/Post-meal value at Baseline) + (Mean Pre/Post-meal value at Day 21- Mean Pre/Post-meal value at Baseline) + (Mean Pre/Post-meal value at Day 7- Mean Pre/Post-meal value at Baseline)]/ 3) over multiple time points listed in Time Frame. The mean pre-meal and post-meal values for baseline, day7, day 21 and day28 were used for comparison.</description>
          <population>Mixed Model Inferential Statistical Analysis of 7 point glucose change from day 1-day 28 Evaluable Population (n=73). Some of the samples collected were not viable and could not be included in the analysis. The total samples collected were still the same but since they could not be included in the analysis the exact number analyzed is referenced.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 day change in Pre-meal Glucose Level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.50" spread="32.343"/>
                    <measurement group_id="O2" value="-8.96" spread="61.561"/>
                    <measurement group_id="O3" value="-25.51" spread="42.198"/>
                    <measurement group_id="O4" value="-53.78" spread="45.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 day change in Post-meal Glucose Level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.98" spread="33.966"/>
                    <measurement group_id="O2" value="10.56" spread="44.944"/>
                    <measurement group_id="O3" value="-34.25" spread="77.268"/>
                    <measurement group_id="O4" value="-50.33" spread="60.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Average Change in Pre-meal Glucose Level</non_inferiority_desc>
            <p_value>0.011</p_value>
            <method>ANCOVA</method>
            <method_desc>Total daily dose is twice the respective dose Pairwise comparison using Treatment D as the reference group</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Average Change in Pre-meal Glucose Level</non_inferiority_desc>
            <p_value>0.0152</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Average Change in Pre-meal Glucose Level</non_inferiority_desc>
            <p_value>0.0284</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Average Change in Post-meal Glucose Level</non_inferiority_desc>
            <p_value>0.1273</p_value>
            <method>ANCOVA</method>
            <method_desc>Total daily dose is twice the respective dose Pairwise comparison using Treatment D as the reference group</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Average Change in Post-meal Glucose Level</non_inferiority_desc>
            <p_value>0.0085</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Average Change in Post-meal Glucose Level</non_inferiority_desc>
            <p_value>0.1289</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Insulin Absolute and Incremental Meal Tolerance Test Area Under the Curve (AUC) 0-2hr</title>
        <description>Change in meal tolerance test insulin area under the curve (0-2 hr) from Day 1 to Day 28 for fixed-dose leucine and metformin combination treatments.</description>
        <time_frame>Baseline,Day 28</time_frame>
        <population>Mixed Model Inferential Statistical Analysis of Plasma Insulin AUC and Incremental AUC change from day 1-day 28 Evaluable Population (n=73). Some samples collected were not viable. The total samples collected were still the same but since they couldn't included in the analysis, exact number analyzed is referenced.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC125</title>
            <description>Leucine 1100mg +Metformin 125mg</description>
          </group>
          <group group_id="O2">
            <title>FDC250</title>
            <description>Leucine 1100mg +Metformin 250mg</description>
          </group>
          <group group_id="O3">
            <title>FDC500</title>
            <description>Leucine 1100mg +Metformin 500mg</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Day 1-14: 500mg, Day 15-28: 850mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Insulin Absolute and Incremental Meal Tolerance Test Area Under the Curve (AUC) 0-2hr</title>
          <description>Change in meal tolerance test insulin area under the curve (0-2 hr) from Day 1 to Day 28 for fixed-dose leucine and metformin combination treatments.</description>
          <population>Mixed Model Inferential Statistical Analysis of Plasma Insulin AUC and Incremental AUC change from day 1-day 28 Evaluable Population (n=73). Some samples collected were not viable. The total samples collected were still the same but since they couldn't included in the analysis, exact number analyzed is referenced.</population>
          <units>h*ulU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma Insulin Absolute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="74.531"/>
                    <measurement group_id="O2" value="-5.64" spread="31.360"/>
                    <measurement group_id="O3" value="-9.59" spread="34.987"/>
                    <measurement group_id="O4" value="-18.06" spread="35.473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Insulin Incremental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" spread="67.120"/>
                    <measurement group_id="O2" value="-4.25" spread="29.514"/>
                    <measurement group_id="O3" value="-9.99" spread="27.956"/>
                    <measurement group_id="O4" value="-15.91" spread="26.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Plasma Insulin Absolute AUC(0-2hr) (h*uIU/mL)</non_inferiority_desc>
            <p_value>0.3143</p_value>
            <method>ANCOVA</method>
            <method_desc>Total daily dose is twice the respective dose. Pairwise comparison using Treatment D as the reference group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Plasma Insulin Absolute AUC(0-2hr) (h*uIU/mL)</non_inferiority_desc>
            <p_value>0.5677</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Plasma Insulin Absolute AUC(0-2hr) (h*uIU/mL)</non_inferiority_desc>
            <p_value>0.8407</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in Fasting Plasma Insulin Concentration</title>
        <description>Effect on fasting plasma insulin concentrations across fixed-dose leucine and metformin combination treatments or the standard metformin reference treatment was evaluated.</description>
        <time_frame>Baseline, Day 28</time_frame>
        <population>Mixed Model Inferential Statistical Analysis of Plasma Insulin AUC and Incremental AUC change from day 1-day 28 Evaluable Population (n=73). Some collected were not viable. So, the total samples collected were still the same but since they could not be included in the analysis the exact number analyzed is referenced.</population>
        <group_list>
          <group group_id="O1">
            <title>FDC125</title>
            <description>Leucine 1100mg +Metformin 125mg</description>
          </group>
          <group group_id="O2">
            <title>FDC250</title>
            <description>Leucine 1100mg +Metformin 250mg</description>
          </group>
          <group group_id="O3">
            <title>FDC500</title>
            <description>Leucine 1100mg +Metformin 500mg</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Day 1-14: 500mg, Day 15-28: 850mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in Fasting Plasma Insulin Concentration</title>
          <description>Effect on fasting plasma insulin concentrations across fixed-dose leucine and metformin combination treatments or the standard metformin reference treatment was evaluated.</description>
          <population>Mixed Model Inferential Statistical Analysis of Plasma Insulin AUC and Incremental AUC change from day 1-day 28 Evaluable Population (n=73). Some collected were not viable. So, the total samples collected were still the same but since they could not be included in the analysis the exact number analyzed is referenced.</population>
          <units>h*uIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="6.652"/>
                    <measurement group_id="O2" value="-0.74" spread="4.069"/>
                    <measurement group_id="O3" value="0.20" spread="7.278"/>
                    <measurement group_id="O4" value="-1.03" spread="7.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9789</p_value>
            <method>ANCOVA</method>
            <method_desc>Total daily dose is twice the respective dose Pairwise comparison using Treatment D as the reference group</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.841</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.748</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>Treatment-Energent Adverse Event (TEAE) is defined as an adverse event occurring on or after the first dose of randomized study medication, or existing prior to the time of and worsening after the time of the first dose of randomized study medication. Subjects experiencing multiple episodes of a given adverse event are counted once. This was a 28 day study and adverse event reporting went upto day 30.</desc>
      <group_list>
        <group group_id="E1">
          <title>FDC125</title>
          <description>Leucine 1100mg +Metformin 125mg</description>
        </group>
        <group group_id="E2">
          <title>FDC250</title>
          <description>Leucine 1100mg +Metformin 250mg</description>
        </group>
        <group group_id="E3">
          <title>FDC500</title>
          <description>Leucine 1100mg +Metformin 500mg</description>
        </group>
        <group group_id="E4">
          <title>Control</title>
          <description>Day 1-14: 500mg, Day 15-28: 850mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lacunar Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric Disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Food</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara Cannon</name_or_title>
      <organization>NuSirt Biopharma</organization>
      <phone>6156567898</phone>
      <email>BCannon@nusirt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

